Pancreatic islet perifusion.

FW Francis S. Willard
JD Jonathan D. Douros
MG Maria B.N. Gabe
AS Aaron D. Showalter
DW David B. Wainscott
TS Todd M. Suter
MC Megan E. Capozzi
WV Wijnand J.C. van der Velden
CS Cynthia Stutsman
GC Guemalli R. Cardona
SU Shweta Urva
PE Paul J. Emmerson
JH Jens J. Holst
DD David A. D’Alessio
MC Matthew P. Coghlan
MR Mette M. Rosenkilde
JC Jonathan E. Campbell
KS Kyle W. Sloop
ask Ask a question
Favorite

For islet perifusion, 75 islets were handpicked and loaded into 0.275 mL chambers containing KRPH (140 mM NaCl, 4.7 mM KCl, 1.5 mM CaCl2, 1 mM NaH2PO4, 1 mM MgSO4, 5 mM HEPES, 2 mM NaHCO3, 1% fatty acid-free BSA) in 2.7 mM glucose. Upon initiation of the perifusion experiment, KRPH with 2.7 mM glucose + 1% BSA was perifused at a rate of 200 μL/min for 24 minutes, followed by KRPH with 2.7 mM glucose +0.1% BSA, to provide an equilibration period for the islets. Following equilibration, experimental conditions were applied, and perifusate was collected each minute. GLP-1 and GIP were diluted in KRPH prior to experiment. Perifusate insulin concentrations were measured with AlphaLISA (PerkinElmer). The following concentrations were used for each reagent: GLP-1, 300 pM; GIP, 3 nM; tirzepatide, 1 nM; GIPR antagonist, 300 nM; exendin-4(9–39) (Ex9), 1 μM.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A